FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291151823> ?p ?o ?g. }

• W4291151823 abstract "Atopic dermatitis (AD) is regarded as a chronic systemic disease which is characterized by a robust overexpression of type 2 related cytokines, with increased total IgE levels and a concomitant sensitization to common allergens. Dupilumab, a fully human monoclonal antibody (mAb) to IL-4Rα that inhibits both IL-4 and IL-13 signaling, has previously shown a marked and rapid improvement when treating the moderate-to-severe forms of AD. We sought to evaluate the real-world evidence (RWE) of dupilumab in the modulation of total and specific IgE (sIgE) serum levels to a panel of molecular house dust mites (HDM) and storage mites (SM) allergens in patients with severe AD.Demographic and clinical data for severe AD adult patients receiving dupilumab treatment (300 mg every 2 weeks) were reviewed. Mean (standard deviations SD) values and percent changes from baseline in total and sIgE to the complete HDM and SM extracts, and 14 individual molecular allergens were measured over 52 weeks.Significant (p < 0.05) changes in mean total IgE levels were observed from baseline to week-52 after treatment with dupilumab. Despite no changes were found in sIgE against the extract of HDM during the 52-week treatment with dupilumab, baseline mean levels from 7 out of 14 individual molecular mite allergens -Der p 1, Der p 2, Der p 5, Der p 7, Der p 21, Der p 23, and Lep d 2- were significantly (p < 0.05) decreased-after 52 weeks of treatment with dupilumab.Dupilumab therapy for 52 weeks resulted in a profound reduction in blood levels of total IgE and allergen-specific IgE to both HDM and SM at the molecular level in adults with severe AD under RWE conditions. The potential benefits of these concomitant immunomodulatory effects after treatment with dupilumab should be explored to a greater extent." @default.
• W4291151823 created "2022-08-13" @default.
• W4291151823 creator A5023280910 @default.
• W4291151823 creator A5036240035 @default.
• W4291151823 creator A5047843334 @default.
• W4291151823 creator A5081168398 @default.
• W4291151823 date "2022-08-12" @default.
• W4291151823 modified "2023-10-01" @default.
• W4291151823 title "Dupilumab modulates specific IgE mite responses at the molecular level in severe T2-high atopic dermatitis: A real-world experience" @default.
• W4291151823 cites W1929911893 @default.
• W4291151823 cites W2012868073 @default.
• W4291151823 cites W2045336002 @default.
• W4291151823 cites W2055052437 @default.
• W4291151823 cites W2057940993 @default.
• W4291151823 cites W2062574496 @default.
• W4291151823 cites W2082609041 @default.
• W4291151823 cites W2112571043 @default.
• W4291151823 cites W2118630839 @default.
• W4291151823 cites W2125896682 @default.
• W4291151823 cites W2148459384 @default.
• W4291151823 cites W2290475350 @default.
• W4291151823 cites W2322518761 @default.
• W4291151823 cites W2396875337 @default.
• W4291151823 cites W2514609206 @default.
• W4291151823 cites W2605967522 @default.
• W4291151823 cites W2773607015 @default.
• W4291151823 cites W2801573893 @default.
• W4291151823 cites W2802109314 @default.
• W4291151823 cites W2811037313 @default.
• W4291151823 cites W2892288216 @default.
• W4291151823 cites W2903856687 @default.
• W4291151823 cites W2907756900 @default.
• W4291151823 cites W2917500720 @default.
• W4291151823 cites W2955692372 @default.
• W4291151823 cites W2973562284 @default.
• W4291151823 cites W2988092601 @default.
• W4291151823 cites W3015549187 @default.
• W4291151823 cites W3048314100 @default.
• W4291151823 cites W3105761540 @default.
• W4291151823 cites W3124764718 @default.
• W4291151823 cites W3131813990 @default.
• W4291151823 cites W3164034400 @default.
• W4291151823 cites W3213796055 @default.
• W4291151823 cites W3214321974 @default.
• W4291151823 cites W4200322457 @default.
• W4291151823 cites W4200469392 @default.
• W4291151823 doi "https://doi.org/10.3389/fmed.2022.939598" @default.
• W4291151823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36035412" @default.
• W4291151823 hasPublicationYear "2022" @default.
• W4291151823 type Work @default.
• W4291151823 citedByCount "2" @default.
• W4291151823 countsByYear W42911518232023 @default.
• W4291151823 crossrefType "journal-article" @default.
• W4291151823 hasAuthorship W4291151823A5023280910 @default.
• W4291151823 hasAuthorship W4291151823A5036240035 @default.
• W4291151823 hasAuthorship W4291151823A5047843334 @default.
• W4291151823 hasAuthorship W4291151823A5081168398 @default.
• W4291151823 hasBestOaLocation W42911518231 @default.
• W4291151823 hasConcept C126322002 @default.
• W4291151823 hasConcept C141105273 @default.
• W4291151823 hasConcept C159654299 @default.
• W4291151823 hasConcept C203014093 @default.
• W4291151823 hasConcept C207480886 @default.
• W4291151823 hasConcept C2776173921 @default.
• W4291151823 hasConcept C2776217527 @default.
• W4291151823 hasConcept C2778166374 @default.
• W4291151823 hasConcept C2778329239 @default.
• W4291151823 hasConcept C2779134260 @default.
• W4291151823 hasConcept C2779384505 @default.
• W4291151823 hasConcept C2779711295 @default.
• W4291151823 hasConcept C2779824493 @default.
• W4291151823 hasConcept C2780501606 @default.
• W4291151823 hasConcept C2780699399 @default.
• W4291151823 hasConcept C59822182 @default.
• W4291151823 hasConcept C71924100 @default.
• W4291151823 hasConcept C86803240 @default.
• W4291151823 hasConceptScore W4291151823C126322002 @default.
• W4291151823 hasConceptScore W4291151823C141105273 @default.
• W4291151823 hasConceptScore W4291151823C159654299 @default.
• W4291151823 hasConceptScore W4291151823C203014093 @default.
• W4291151823 hasConceptScore W4291151823C207480886 @default.
• W4291151823 hasConceptScore W4291151823C2776173921 @default.
• W4291151823 hasConceptScore W4291151823C2776217527 @default.
• W4291151823 hasConceptScore W4291151823C2778166374 @default.
• W4291151823 hasConceptScore W4291151823C2778329239 @default.
• W4291151823 hasConceptScore W4291151823C2779134260 @default.
• W4291151823 hasConceptScore W4291151823C2779384505 @default.
• W4291151823 hasConceptScore W4291151823C2779711295 @default.
• W4291151823 hasConceptScore W4291151823C2779824493 @default.
• W4291151823 hasConceptScore W4291151823C2780501606 @default.
• W4291151823 hasConceptScore W4291151823C2780699399 @default.
• W4291151823 hasConceptScore W4291151823C59822182 @default.
• W4291151823 hasConceptScore W4291151823C71924100 @default.
• W4291151823 hasConceptScore W4291151823C86803240 @default.
• W4291151823 hasFunder F4320309967 @default.
• W4291151823 hasLocation W42911518231 @default.
• W4291151823 hasLocation W42911518232 @default.
• W4291151823 hasLocation W42911518233 @default.
• W4291151823 hasOpenAccess W4291151823 @default.
• W4291151823 hasPrimaryLocation W42911518231 @default.

• next